Effect of structural modifications on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats

Journal of Applied Toxicology

Volumn 32, Issue 2, 2012, Pages 108-117

  Patel, Niti N ^a   Crincoli, Christine M ^a   Frederick, Douglas M ^a   Tchao, Ruy ^a   Harvison, Peter J ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

3 (3,5 dichlorophenyl) 2,4 thiazolidinedione; Hepatotoxicity; Rat; Structure activity relationship; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 (3,5 DICHLOROPHENYL) 2 THIAZOLIDINONE; 3 (3,5 DICHLOROPHENYL) 4 THIAZOLIDINONE; 3 (3,5 DICHLOROPHENYL) 5 METHYL 2,4 THIAZOLIDINEDIONE; 3 (3,5 DIMETHYLPHENYL) 2,4 THIAZOLIDINEDIONE; 3 (3,5' DICHLOROPHENYL) 2,4 THIAZOLIDINEDIONE; 3 (4 CHLOROPHENYL) 2,4 THIAZOLIDINEDIONE; 3 [3,5 BIS(TRIFLUOROMETHYL)PHENYL] 2,4 THIAZOLIDINEDIONE; 3 PHENYL 2,4 THIAZOLIDINEDIONE; [[[(3,5 DICHLOROPHENYL)AMINO]CARBONYL]THIO]ACETIC ACID; ALANINE AMINOTRANSFERASE; CORN OIL; NITROGEN; PHENYL GROUP; THIOGLYCOLIC ACID; UNCLASSIFIED DRUG; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FISCHER 344 RAT; ISOMER; KIDNEY MASS; LIVER STRUCTURE; LIVER TOXICITY; LIVER WEIGHT; MALE; METHYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; UREA NITROGEN BLOOD LEVEL; URINE VOLUME;

ALANINE TRANSAMINASE; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; LIVER DISEASES; MALE; RATS; RATS, INBRED F344; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINEDIONES;

ANIMALIA; RATTUS; ZEA MAYS;

EID: 84855247783     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1639     Document Type: Article

References (41)

1. Ali AM, Saber GE, Mahfouz NM, El-Gendy MA, Radwan AA, Hamid MA. 2007. Synthesis and three-dimensional qualitative structure selectivity relationships of 3, 5-disubstituted-2, 4-thiazolidinedione derivatives as COX2 inhibitors. Arch. Pharm. Res. 30: 1186-1204.
2. Baughman TM, Graham RA, Wells-Knecht K, Silver IS, Tyler LO, Wells-Knecht M, Zhao K. 2005. Metabolic activation of pioglitazone identified from rat and human liver microsomes and freshly isolated hepatocytes. Drug Metab. Dispos. 33: 733-738.
3. Brouwer WG, Blem AR. 1987. Substituted thiazolidinones useful as plant growth regulators. US patent 4, 664, 694.
4. Brown WE, Green AH, Cedel TE, Cairns J. 1987. Biochemistry of protein-isocyanate interactions: A comparison of the effects of aryl vs. alkyl isocyanates. Environ. Health Perspect. 72: 5-11.
5. Bruno G, Costantino L, Curinga C, Maccari R, Monforte F, Nicolo F, Ottana R, Vigorita MG. 2002. Synthesis and aldose reductase inhibitory activity of 5-arylidene-2, 4-thiazolidinediones. Bioorg. Med. Chem. 10: 1077-1084.
6. Chojkier M. 2005. Troglitazone and liver injury: In search of answers. Hepatology 41: 237-246.
7. Crincoli CM, Patel NN, Tchao R, Harvison PJ. 2008. Role of biotransformation in 3-(3, 5-dichlorophenyl)-2, 4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats. Toxicology. 250: 100-108.
8. Cui D, Rankin GO, Harvison PJ. 2005. Metabolism of the nephrotoxicant N-(3, 5-dichlorophenyl)succinimide in rats: evidence for bioactivation through alcohol-O-glucuronidation and O-sulfation. Chem. Res. Toxicol. 18: 991-1003.
9. Czerniak R. 2001. Gender-based differences in pharmacokinetics in laboratory animal models. Int. J. Toxicol. 20: 161-163.
10. Dalich GM, Larson RE. 1985. Temporal and dose-response of monochlorobenzene hepatotoxicity in rats. Fund. Appl. Toxicol. 5: 105-116.
11. El-Naggar MHM, Helmy A, Moawad M, Al-Omary M, Al-Kadhi Y, Habib B. 2008. Late-onset rosiglitazone-associated acute liver failure in a patient with Hodgkin's lymphoma. Ann. Pharmacother. 42: 713-718.
12. Fujinami AA, Nodera KN, Tanaka KT, Hyogo OT, Yamamoto ST, Akiba KI, Ooishi TM. 1968. German patent 1, 953, 431.
13. Fujinami A, Ozaki T, Yamamoto S. 1971. Studies on biological activity of cyclic imide compounds. Part I. Antimicrobial activity of 3-phenyloxazolidine-2, 4-diones and related compounds. Agric. Biol. Chem. 35: 1707-1719.
14. Giaginis C, Tsantili-Kakoulidou A. 2008. Alternative measures of lipophilicity: from octanol-water partitioning to IAM retention. J. Pharm. Sci. 97: 2984-3004.
15. Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. 1998. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann. Intern. Med. 129: 36-38.
16. Gouda HE, Khan A, Schwartz J, Cohen RI. 2001. Liver failure in a patient treated with long-term rosiglitazone therapy. Am. J. Med. 111: 584-585.
17. Graham DJ, Green L, Senior JR, Nourjah P. 2003. Troglitazone-induced liver failure: a case study. Am. J. Med. 114: 299-306.
18. He K, Talaat RE, Pool WF, Reily MD, Reed JE, Bridges AJ, Woolf TF. 2004. Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. Drug Metab. Dispos. 32: 639-646.
19. Kassahun K, Pearson PG, Tang W, McIntosh I, Leung K, Elmore C, Dean O, Wang R, Doss G, Baillie TA. 2001. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. 14: 62-70.
20. Kennedy EL, Tchao R, Harvison PJ. 2003. Nephrotoxic and hepatotoxic potential of imidazolidinedione-, oxazolidinedione-, and thiazolidinedione-containing analogues of N-(3, 5-dichlorophenyl)succinimide (NDPS) in Fischer 344 rats. Toxicology 186: 79-91.
21. Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. 2000. Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am. J. Gastroenterol. 95: 272-276.
22. Low LK, Meeks JR, Mackerer CR. 1989. Health effects of the alkylbenzenes. II. Xylenes. Toxicol. Ind. Health. 5: 85-105.
23. Luo Y, Ma L, Zheng H, Chen L, Li R, He C, Yang S, Ye X, Chen Z, Li Z, Gao Y, Han J, He G, Yang L, Wei Y. 2010. Discovery of (Z)-5-(4-methoxybenzylidene)thiazolidine-2, 4-dione, a readily available and orally active glitazone for the treatment of concanavalin A-induced acute liver injury of BALB/c mice. J. Med. Chem. 53: 273-281.
24. Machacek V, Sterba V, Zahradnickova H. 1981. Solvolysis kinetics and mechanism of 3-methyl-1, 3-thiazolidine-2, 4-dione. Coll. Czech. Chem. Commun. 46: 3097-3103.
25. Maeda K. 2001. Hepatocellular injury in a patient receiving pioglitazone. Ann. Intern. Med. 135: 306.
26. Marcy TR, Britton ML, Blevins SM. 2004. Second-generation thiazolidinediones and hepatotoxicity. Ann. Pharmacother. 38: 1419-1423.
27. Mugford C, Kedderis G. 1998. Sex-dependent metabolism of xenobiotics. Drug. Metab. Rev. 30: 441-498.
28. Patel NN, Crincoli CM, Kennedy EL, Frederick DM, Tchao R, Harvison PJ. 2008. Effect of gender, dose and time on 3-(3, 5-dichlorophenyl)-2, 4-thiazolidinedione (DCPT)-induced hepatotoxicity in Fischer 344 rats. Xenobiotica 38: 435-449.
29. Rakowitz D, Maccari R, Ottana R, Vigorita MG. 2006. In vitro aldose reductase inhibitory activity of 5-benzyl-2, 4-thiazolidinediones. Bioorg. Med. Chem. 14: 567-574.
30. Rankin GO. 1982. Nephrotoxicity following acute administration of N-(3, 5-dichlorophenyl)succinimide in rats. Toxicology 23: 21-31.
31. Rankin GO. 2004. Nephrotoxicity induced by C- and N-arylsuccinimides. J. Toxicol. Environ. Health, Pt B 7: 399-416.
32. Scheen AJ. 2001. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Safety 24: 873-888.
33. Selander HG, Jerina DM, Daly JW. 1975. Metabolism of chlorobenzene with hepatic microsomes and solubilized cytochrome P450 systems. Arch. Biochem. BIophys. 168: 309-321.
34. Stine ER, Gunawardhana L, Sipes IG. 1991. The acute hepatotoxicity of the isomers of dichlorobenzene in Fischer-344 and Sprague-Dawley rats: isomer-specific and strain-specific differential toxicity. Toxicol. Appl. Pharmacol. 109: 472-481.
35. Tashiro K, Nakamura M. 1985. 3-Substituted 2(3 H)-benzothiazolones. JP patent 60-166673. [Procedure from Patent Abstracts of Japan (English translation)].
36. Tettey JN, Maggs JI, Rapeport WG, Piromohamed M, Park BK. 2001. Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem. Res. Toxicol. 14: 965-974.
37. Toldy L, Borsi J, Elek S, Elekes I, Andrasi F. 1972. Certain 3-(2, 6-dichlorophenyl)-2-iminothiazolidines. US patent 3, 671, 537.
38. Valentovic MA, Ball JG, Anestis D, Madan E. 1993. Acute hepatic and renal toxicity of dichlorobenzene isomers in Fischer 344 rats. J. Appl. Toxicol. 13: 1-7.
39. van Doorn R, Bos RP, Brouns RME, Leijdekkers Ch-M, Henderson PTh. 1980. Effect of toluene and xylenes on liver glutathione and their urinary excretion as mercapturic acids in the rat. Arch. Toxicol. 43: 293-304.
40. van de Waterbeemd H, Smith DA, Jones BC. 2001. Lipophilicity in PK design: methyl, ethyl, futile. J. Comput. Aided Mol. Des. 15: 273-286.
41. Yang J, Wei S, Wang D-S, Wang Y-C, Kulp SK, Chen C-S. 2008. Pharmacological exploitation of the peroxisome proliferator-activated receptor γ agonist ciglitazone to develop a novel class of androgen-receptor-ablative agents. J. Med. Chem. 51: 2100-2107.